Women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are
candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 …

The goal of this study was to characterize the relationship between tumor uptake of 64 Cu-DOTA-trastuzumab
as measured by PET/CT and standard, immunohistochemistry (IHC)-based…

Background: PET imaging using radiolabeled immunoconstructs shows promise in cancer
detection and in assessing tumor response to therapies. The authors report the first-in-human …

We hypothesized that functional imaging with 64 Cu-DOTA-trastuzumab PET/CT would predict
the response to the antibody–drug conjugate trastuzumab–emtansine (T-DM1). Methods: …

The development of improved breast cancer screening methods is hindered by a lack of
cancer-specific imaging agents and effective small-animal models to test them. The purpose of …

The high specificity and favorable pharmacological properties of monoclonal antibodies (mAbs)
have prompted significant interest in re-engineering this class of molecules to add novel …

Objective To describe the application of pharmaceutical care practices in the administration
of new therapeutic radiopharmaceuticals used in the treatment of non-Hodgkin’s lymphoma (…

Objective Human epidermal growth factor receptor 2 (HER2) is an important biomarker for
targeted gastric cancer (GC) immunotherapy. However, heterogeneous HER2 overexpression …

Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are
candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 …

Objectives Because the potential exists for accidental radiation exposure from volatile 131 I
when handling 131 I tositumomab in large quantities (up to 200 mCi), the objectives of this …